Options when bone is limited
In 2026 the FDA cleared an indication for Ø3.75 × 18 mm BLC implants in the pterygoid region of the upper jaw, for splinted multi-unit restorations only. 2
The ITI consensus report on zygomatic implants found mean long-term zygomatic implant survival of 96.2% over a mean follow-up of 6.3 years, with sinusitis occurring in 14.2% of cases. 4
These pooled figures cover zygomatic implants in general, not one manufacturer's system.
Last updated 28 Sep 2026 · How we review
Sources
- Manufacturer documentationStraumann® Pro Arch™ Fixed Solution — Institut Straumann AG. Accessed 28 Sep 2026.
- Regulatory recordFDA 510(k) K252168 — Straumann BLC Implants — indication widening (pterygoid) — U.S. Food and Drug Administration, 2026-03-10. Accessed 28 Sep 2026.
- Manufacturer documentationStraumann® Zygomatic Implant System (product page) — Institut Straumann AG. Accessed 28 Sep 2026.
- Consensus / guidelineAl-Nawas B et al. ITI consensus report on zygomatic implants — Int J Implant Dent, 2023. Accessed 28 Sep 2026.
Educational information only. The choice of implant system depends on your anatomy, restorative plan, bone quality and the clinician's assessment. This website does not recommend a specific implant for you.